BiotechTube
MultiOmic Health

MultiOmic Health

London, United Kingdom· Est.
multiomic.health
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

MultiOmic Health is an AI-driven precision medicine company targeting the massive and costly cardio-renal-metabolic disease space. The company has built a proprietary platform that uses multi-omics data and longitudinal clinical phenotyping to discover patient subgroups and develop targeted therapeutics and companion diagnostics. Led by a seasoned team with deep biopharma and data science experience, the company is in a pre-clinical, pre-revenue stage, building a global patient registry and advancing its initial programs in chronic kidney disease.

Chronic Kidney DiseaseCardio-Renal-Metabolic Diseases

Technology Platform

AI-enabled platform integrating deep longitudinal patient multi-omics data with clinical phenotyping to identify patient subpopulations (endotypes) and discover stratified drug targets and companion diagnostics.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The massive and growing $2+ trillion cardio-renal-metabolic disease market presents a vast addressable opportunity for effective precision therapies.
MultiOmic's AI-driven endotyping approach could significantly de-risk drug development in this space, creating high-value partnership opportunities with large pharma companies seeking improved R&D productivity.

Risk Factors

The company faces significant scientific risk in translating AI-derived insights into clinically effective therapeutics, a process with historically high attrition.
Operational execution risk in building a large-scale global patient registry and securing ongoing funding as a pre-revenue entity are also key challenges.

Competitive Landscape

MultiOmic operates in the competitive AI-driven drug discovery space, facing rivals ranging from large tech-bio hybrids (e.g., Recursion, Insilico Medicine) to pharma internal initiatives. Its differentiation lies in its specific focus on deep multi-omics integration and longitudinal phenotyping for the heterogeneous CRM disease continuum.

More companies in United Kingdom →